KLF | DHS | Cs | FAIRE | H3K4me1 | H3K27ac | GATA-1 | NF-E2 | minP | KLF-P |
---|
| | | K562 | K562 | K562 | HeLa | HEK293 |
---|
KLF1
| I | Y | Y | Y | | | | | | | |
II | Y | Y | Y* | Y* | Y | | Y | Y | | |
III | Y | | Y* | Y* | Y | | Y | Y | | |
IV | Y | Y | | Y* | Y | | Y | Y | | |
V | | Y | Y* | Y* | | Y | Y | Y | | |
KLF2
| I | Y | Y | Y | Y | Y | | Y | Y | | Y |
KLF3
| I | Y | Y | Y | Y* | | | | Y | Y | Y |
II | Y | Y | Y | Y* | | | | | | Y |
III | Y | Y | Y | Y | | | Y | Y | | Y |
KLF6
| I | Y | Y | Y | Y | | | Y | | | |
II | | | Y | Y | | | | Y | | |
III | Y | | Y | Y* | | | | Y | | |
IV | Y | | Y | Y* | | | Y | Y | | |
KLF9
| I | | Y | Y* | Y* | Y | | Y | Y | | |
II | | Y | Y | | Y | | Y | Y | | |
KLF10
| I | | | Y* | | | | Y | | | |
KLF11
| I | Y | Y | Y | Y* | | | Y | Y | Y | |
KLF13
| I | | | Y* | | | | | | | |
II | | | Y* | | | | Y | | | |
III | | | Y | | | | | Y | | |
KLF16
| I | | Y | Y* | Y* | | | Y | | | |
II | Y | Y | Y | Y | | | | | | |
KLF17
| I | Y | Y | Y* | Y* | | | Y | Y | Y | |
- DHS conservation (Cs) was observed across 32 placental mammals, including humans, chimps, mice, and rabbits. The chromatin accessibility using FAIRE, enhancer-associated histone modifications (H3K4me1 and H3K27ac), and TFBSs for erythroid GATA-1 and NF-E2 on DHSs in erythroid K562 cells were extracted from UCSC Genome Browser. The enhancers characterized from the erythroid-specific or putative erythroid-specific DHSs were summarized in the last four columns. Y: yes. *: this histone modification is K562 specific or putative K562 specific.